Authors: SALEH MN LOBUGLIO AF POSEY JA OSTROFF JB KHOR SP THURMOND LM BIGLEY JW

Citation: Mn. Saleh et al., PHASE-I STUDY OF DIFFERENT SCHEDULES OF THE HUMANIZED ANTI-EGP40 MOAB3622W94 IN PATIENTS WITH ANTIGEN-EXPRESSING EPITHELIAL TUMORS, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 13(1), 1998, pp. 8-8

Authors: SCHILSKY RL HOHNEKER J RATAIN MJ JANISCH L SMETZER L LUCAS VS KHOR SP DIASIO R VONHOFF DD BURRIS HA

Citation: Rl. Schilsky et al., PHASE-I CLINICAL AND PHARMACOLOGICAL STUDY OF ENILURACIL PLUS FLUOROURACIL IN PATIENTS WITH ADVANCED CANCER, Journal of clinical oncology, 16(4), 1998, pp. 1450-1457

Authors: CHOW HH KHOR SP LEE HC MAYERSOHN M

Citation: Hh. Chow et al., A MODIFIED EQUILIBRIUM DIALYSIS TECHNIQUE FOR MEASURING PLASMA-PROTEIN BINDING - EXPERIMENTAL EVALUATION WITH DIAZEPAM AND NORTRIPTYLINE, Pharmaceutical research, 15(10), 1998, pp. 1643-1646

Authors: KHOR SP AMYX H DAVIS ST NELSON D BACCANARI DP SPECTOR T

Citation: Sp. Khor et al., DIHYDROPYRIMIDINE DEHYDROGENASE INACTIVATION AND 5-FLUOROURACIL PHARMACOKINETICS - ALLOMETRIC SCALING OF ANIMAL DATA, PHARMACOKINETICS AND TOXICODYNAMICS OF 5-FLUOROURACIL IN HUMANS, Cancer chemotherapy and pharmacology, 39(3), 1997, pp. 233-238

Authors: JEWELL RC KHOR SP KISOR DF LACROIX KAK WARGIN WA

Citation: Rc. Jewell et al., PHARMACOKINETICS OF RHEOTHRX INJECTION IN HEALTHY MALE-VOLUNTEERS, Journal of pharmaceutical sciences, 86(7), 1997, pp. 808-812

Authors: BAKER SD KHOR SP ADJEI AA DOUCETTE M SPECTOR T DONEHOWER RC GROCHOW LB SARTORIUS SE NOE DA HOHNEKER JA ROWINSKY EK

Citation: Sd. Baker et al., PHARMACOKINETIC, ORAL BIOAVAILABILITY, AND SAFETY STUDY OF FLUOROURACIL IN PATIENTS TREATED WITH 776C85, AN INACTIVATOR OF DIHYDROPYRIMIDINE DEHYDROGENASE, Journal of clinical oncology, 14(12), 1996, pp. 3085-3096